Predict your next investment

Corporation
HEALTHCARE | Biotechnology
innate-pharma.com

See what CB Insights has to offer

Founded Year

1999

Stage

Corporate Minority - P2P | IPO

Total Raised

$50M

Market Cap

0.32B

About Innate Pharma

Innate Pharma is a biopharmaceutical company that develops drugs to target innate immunity. The Company is developing three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings. Innate Pharma's drug candidates also have development potential in the treatment of infectious disease and chronic inflammation.

Innate Pharma Headquarter Location

117, Avenue de Luminy - BP 30191

Marseille, 13009,

France

33 (0)4 30 30 30 30

Latest Innate Pharma News

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

Jan 5, 2022

01/05/2022 | 01:01am EST Message : Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has obtained €28.7M in non-dilutive financing in the form of two loans from Société Générale and BNP Paribas. The two loans have an initial term of one year with a five-year extension option. They are 90% guaranteed by the French state as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. “This additional financing provides the opportunity to further strengthen our cash position as well as our research and development activities in France. We thank our bank partners, Société Générale and BNP Paribas, for their support,” said Frederic Lombard, Senior Vice President and Chief Financial Officer, Innate Pharma. About Innate Pharma: Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com Information about Innate Pharma shares: ISIN code Disclaimer on forward-looking information and risk factors: This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005828/en/ © Business Wire 2022

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Innate Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Innate Pharma is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Innate Pharma Patents

Innate Pharma has filed 114 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/23/2015

12/28/2021

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Transcription factors

Grant

Application Date

6/23/2015

Grant Date

12/28/2021

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Transcription factors

Status

Grant

Innate Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Innate Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.